These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 29474983)

  • 41. A Novel, Circulating Tumor Cell Enrichment Method Reduces ARv7 False Positivity in Patients with Castration-Resistant Prostate Cancer.
    Nakasato T; Kusaka C; Ota M; Hasebe Y; Ueda K; Unoki T; Oshinomi K; Morita J; Maeda Y; Shichijo T; Naoe M; Ogawa Y
    Diagnostics (Basel); 2020 Mar; 10(3):. PubMed ID: 32168745
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
    Liu L; Dong X
    PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Glycogen synthase kinase-3 inhibitors suppress the AR-V7-mediated transcription and selectively inhibit cell growth in AR-V7-positive prostate cancer cells.
    Nakata D; Koyama R; Nakayama K; Kitazawa S; Watanabe T; Hara T
    Prostate; 2017 Jun; 77(9):955-961. PubMed ID: 28397338
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of an immunofluorescent AR-V7 circulating tumor cell assay - A blood-based test for men with metastatic prostate cancer.
    Lu D; Krupa R; Harvey M; Graf RP; Schreiber N; Barnett E; Carbone E; Jendrisak A; Gill A; Orr S; Scher HI; Schonhoft JD
    J Circ Biomark; 2020; 9():13-19. PubMed ID: 33717359
    [TBL] [Abstract][Full Text] [Related]  

  • 45. DBC1 promotes castration-resistant prostate cancer by positively regulating DNA binding and stability of AR-V7.
    Moon SJ; Jeong BC; Kim HJ; Lim JE; Kwon GY; Kim JH
    Oncogene; 2018 Mar; 37(10):1326-1339. PubMed ID: 29249800
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells.
    Liu L; Lou N; Li X; Xu G; Ruan H; Xiao W; Qiu B; Bao L; Yuan C; Huang X; Wang K; Cao Q; Chen K; Yang H; Zhang X
    Oncol Rep; 2017 Jun; 37(6):3651-3659. PubMed ID: 28498452
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor.
    Dalal K; Morin H; Ban F; Shepherd A; Fernandez M; Tam KJ; Li H; LeBlanc E; Lack N; Prinz H; Rennie PS; Cherkasov A
    Eur J Med Chem; 2018 Sep; 157():1164-1173. PubMed ID: 30193215
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Detecting predictive androgen receptor modifications in circulating prostate cancer cells.
    Steinestel J; Luedeke M; Arndt A; Schnoeller TJ; Lennerz JK; Wurm C; Maier C; Cronauer MV; Steinestel K; Schrader AJ
    Oncotarget; 2019 Jun; 10(41):4213-4223. PubMed ID: 31289619
    [TBL] [Abstract][Full Text] [Related]  

  • 49.
    Markou A; Tzanikou E; Strati A; Zavridou M; Mastoraki S; Bournakis E; Lianidou E
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32397108
    [No Abstract]   [Full Text] [Related]  

  • 50. Prognostic Significance of Gene Expression and DNA Methylation Markers in Circulating Tumor Cells and Paired Plasma Derived Exosomes in Metastatic Castration Resistant Prostate Cancer.
    Zavridou M; Strati A; Bournakis E; Smilkou S; Tserpeli V; Lianidou E
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33668490
    [TBL] [Abstract][Full Text] [Related]  

  • 51. AR-Variant-Positive CTC: A Surrogate for a Surrogate for Taxane Therapy Outcome?
    Dehm SM; Montgomery B; Plymate SR
    Clin Cancer Res; 2019 Mar; 25(6):1696-1698. PubMed ID: 30591516
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gene expression profiling and DNA methylation analyses of CTCs.
    Lianidou ES
    Mol Oncol; 2016 Mar; 10(3):431-42. PubMed ID: 26880168
    [TBL] [Abstract][Full Text] [Related]  

  • 53. AR-V7 detection guides treatment.
    Romero D
    Nat Rev Clin Oncol; 2018 Sep; 15(9):533. PubMed ID: 30018408
    [No Abstract]   [Full Text] [Related]  

  • 54. Circulating tumor cell-based or tissue biopsy-based AR-V7 detection: which provides the greatest clinical utility?
    Rao A; Antonarakis ES
    Ann Transl Med; 2019 Dec; 7(Suppl 8):S354. PubMed ID: 32016072
    [No Abstract]   [Full Text] [Related]  

  • 55. Considerations for AR-V7 testing in clinical routine practice.
    Bernemann C; Krabbe LM; Schrader AJ
    Ann Transl Med; 2019 Dec; 7(Suppl 8):S378. PubMed ID: 32016096
    [No Abstract]   [Full Text] [Related]  

  • 56. AR variants in CTCs correlate with outcomes.
    Fenner A
    Nat Rev Urol; 2019 Mar; 16(3):146. PubMed ID: 30356147
    [No Abstract]   [Full Text] [Related]  

  • 57. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
    Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K
    Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development and Application of Liquid Biopsies in Metastatic Prostate Cancer.
    Morrison GJ; Goldkorn A
    Curr Oncol Rep; 2018 Mar; 20(4):35. PubMed ID: 29572775
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Improved Risk Stratification by Circulating Tumor Cell Counts in Pancreatic Cancer.
    Effenberger KE; Schroeder C; Hanssen A; Wolter S; Eulenburg C; Tachezy M; Gebauer F; Izbicki JR; Pantel K; Bockhorn M
    Clin Cancer Res; 2018 Jun; 24(12):2844-2850. PubMed ID: 29559560
    [No Abstract]   [Full Text] [Related]  

  • 60. Expression of AR-V7 and ARv
    Tagawa ST; Antonarakis ES; Gjyrezi A; Galletti G; Kim S; Worroll D; Stewart J; Zaher A; Szatrowski TP; Ballman KV; Kita K; Tasaki S; Bai Y; Portella L; Kirby BJ; Saad F; Eisenberger MA; Nanus DM; Giannakakou P
    Clin Cancer Res; 2019 Mar; 25(6):1880-1888. PubMed ID: 30301829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.